T2Bacteria Panel

Actionable identification of critical infections

The T2Bacteria® Panel, which is currently submitted for FDA clearance in the U.S. and CE Marked in the EU, identifies six of the most deadly and prevalent bacteria species that are often not covered by empiric therapy. The T2Bacteria RUO Panel is currently available for Research Use Only (RUO) in the U.S. As with the FDA-cleared T2Candida® Panel, the T2Bacteria Panel will provide species-specific results directly from whole blood and are available within hours of patient presentation.

Results direct from blood draw

Rapid detection and identification of sepsis-causing pathogens are critical for optimizing antimicrobial therapy to improve patient survival and substantially reduce healthcare costs. Together, the T2Bacteria Panel and the T2Candida Panel are the ONLY tests that can enable 95% of patients with bloodstream infections to receive targeted therapy within hours, when treatment has the most significant impact on patient outcomes.1,2

Rapidly detect and identify species, no blood culture required

Proven technology

Today, implementation of the T2Candida Panel in approximately 130 hospitals globally has shortened length of stay, reduced antimicrobial consumption and identified patients missed by blood culture.

The T2Bacteria Panel, which runs on the same FDA-cleared T2Dx® Instrument as the T2Candida Panel, is deigned to be used on patients presenting in the emergency department or with symptomatic inpatients. Independent studies have proven that rapid detection and treatment can reduce patient mortality by 50% or more, while reducing hospital and ICU length of stay by 3 to 7 days.3,4-9

Timely and accurate results to support clinical action

 Initial empiric antimicrobial therapy effectively treats about 60% of all septic patients.10 By focusing on those pathogens that often do not respond to initial empiric therapy, results from the FDA-cleared T2Candida Panel and the T2Bacteria Panel, once commercially available, may enable the administration of effective therapy within hours of patient presentation and long before blood-culture-based results are available.

Impact of timely, effective sepsis treatment

  • Decreased mortality rates3
  • Shortened length of stay

     

     

    • 3 to 7 ICU days saved4-9
    • 1 to 7 hospital days saved4-9
  • Reduced use of antimicrobial drugs4-9
  • Reduced healthcare spending; savings of ~$25,000 per positive patient4-9,11
  • Improved healthcare quality metrics

T2Bacteria coverage

Gram Negative:

Escherichia coli

Klebsiella pneumoniae

Pseudomonas aeruginosa

Acinetobacter baumannii

Gram positive:

Staphylococcus aureus

Enterococcus faecium

The T2Bacteria Panel identifies ~90% of Gram Negative and ~70% of community-acquired infections seen in the Emergency Department.12,13

……………………………………….
1. Buehler, S. S., Madison, B., Snyder, S. R., Derzon, J. H., Cornish, N. E., Saubolle, M. A., … & Wolk, D. M. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
2. Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., … & Peters, C. (2009). Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. CHEST Journal, 136(5), 1237-1248.
3. Diekema, D. J., Beekmann, S. E., Chapin, K. C., Morel, K. A., Munson, E., & Doern, G. V. (2003). Epidemiology and outcome of nosocomial and community-onset bloodstream infection. Journal of Clinical Microbiology, 41(8), 3655-3660.
4. Stosor V et al. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. 1998 Mar 9;158(5):522-7.
5. Abramson MA et al. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999 Jun;20(6):408-11.
6. Kim BN et al. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002 Oct;52(2):99-106.
7. Sunenshine RH et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007 Jan;13(1):97-103.
8. Micek ST et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11.
9. Tumbarello M et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010 Oct;54(10):4085-91.
10. Buehler, S. S., Madison, B., Snyder, S. R., Derzon, J. H., Cornish, N. E., Saubolle, M. A., … & Wolk, D. M. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
11. Golan, Yoav, et al. Annals of internal medicine 143.12 (2005): 857-869.
12. Tsalik EL et al. Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. J Clin Microbiol. 2010 Jan;48(1):26-33.
13. Luzzaro F et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):849-55.
 
*T2Bacteria is not currently available for commercial sale in the US.